Molex company Phillips-Medisize and Finland-based medtech company GlucoModicum have partnered on an advanced non-invasive, needle-free continuous glucose monitor (CGM).
Claimed to be the first-of-its-kind, the wearable device will be designed and commercialised to eliminate technology and patient-care roadblocks to CGM.
GlucoModicum determined that magnetohydrodynamic (MHD) technology helps in applying a small amount of energy directly to the interstitial fluid to drive it to the skin surface for rapid and easy glucose sample extraction.
With the support of a contract development and manufacturing organisation, GlucoModicum focused on the development of a new device, Talisman, which will adhere to a patient's arm.
The device combines MHD technology, advanced algorithms and ultra-sensitive biosensors while linking to a smartphone app for data collection and reporting.
GlucoModicum has not yet received either the US Food and Drug Administration or CE Mark approval for the Talisman device.
For developing this device, Phillips-Medisize offered its expertise in industrial design, material science, miniaturisation, mechanical and electrical engineering, connectivity and software development.
The company also provided supply chain management, manufacturing, testing, quality assurance and regulatory compliance services.
Phillips-Medisize business development manager Homer Fairley said: “The day we provided the finished sample product to GlucoModicum was a moment of celebration for both parties, as it really brought the possibilities to life.
“Now that there is a proven concept, we look forward to the opportunity to leverage Phillips-Medisize's high-volume manufacturing capabilities to produce hundreds of millions of units on time and in a cost-effective manner."
